Baseline
Animals
Antimalarials
/ therapeutic use
Artemisinins
/ therapeutic use
Aspartic Acid Endopeptidases
/ therapeutic use
DNA Copy Number Variations
Humans
Malaria, Falciparum
/ drug therapy
Plasmodium falciparum
/ drug effects
Protozoan Proteins
/ therapeutic use
Quinolines
/ therapeutic use
Senegal
Treatment Failure
Plasmodium falciparum
antimalarial drug
in vitro
malaria
molecular marker
piperaquine
plasmepsin II
resistance
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
19
11
2018
accepted:
10
02
2019
pubmed:
21
2
2019
medline:
31
3
2020
entrez:
21
2
2019
Statut:
epublish
Résumé
Dihydroartemisinin-piperaquine, which was registered in 2017 in Senegal, is not currently used as the first-line treatment against uncomplicated malaria. A total of 6.6% to 17.1% of
Identifiants
pubmed: 30782997
pii: AAC.02445-18
doi: 10.1128/AAC.02445-18
pmc: PMC6496083
pii:
doi:
Substances chimiques
Antimalarials
0
Artemisinins
0
Protozoan Proteins
0
Quinolines
0
artenimol
6A9O50735X
piperaquine
A0HV2Q956Y
Aspartic Acid Endopeptidases
EC 3.4.23.-
plasmepsin II
EC 3.4.23.39
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2019 American Society for Microbiology.
Références
Lancet. 2018 Apr 7;391(10128):1378-1390
pubmed: 29606364
Malar J. 2016 Oct 21;15(1):519
pubmed: 27769299
Lancet Infect Dis. 2017 Feb;17(2):164-173
pubmed: 27818095
Malar J. 2018 Oct 17;17(1):369
pubmed: 30333022
Antimicrob Agents Chemother. 2015 Aug;59(8):4719-26
pubmed: 26014949
Malar J. 2015 Feb 06;14:60
pubmed: 25849097
Acta Trop. 2018 Sep;185:363-370
pubmed: 29932931
Am J Trop Med Hyg. 2006 Jun;74(6):953-9
pubmed: 16760503
Antimicrob Agents Chemother. 2015;59(6):3018-30
pubmed: 25753626
J Clin Microbiol. 2010 May;48(5):1651-60
pubmed: 20220159
J Infect Dis. 2017 Aug 15;216(4):468-476
pubmed: 28931241
Lancet Infect Dis. 2016 Mar;16(3):357-65
pubmed: 26774243
Nat Commun. 2018 Aug 17;9(1):3314
pubmed: 30115924
Malar J. 2011 Jul 20;10:198
pubmed: 21774826
Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):11672-7
pubmed: 26261345
Malar J. 2013 Jan 24;12:34
pubmed: 23347727
Lancet Infect Dis. 2017 Feb;17(2):174-183
pubmed: 27818097
J Infect Dis. 2017 Nov 15;216(8):1008-1017
pubmed: 28968782
PLoS One. 2009 Sep 28;4(9):e7164
pubmed: 19784374
Antimicrob Agents Chemother. 2001 Jun;45(6):1746-50
pubmed: 11353621
Infection. 2018 Dec;46(6):867-870
pubmed: 29980936
Antimicrob Agents Chemother. 2016 Jul 22;60(8):5010-3
pubmed: 27185795
Antimicrob Agents Chemother. 2018 Oct 24;62(11):
pubmed: 30181370
Emerg Infect Dis. 2017 Jan;24(1):40-48
pubmed: 29260689
Malar J. 2016 Nov 3;15(1):525
pubmed: 27809844
Malar J. 2011 Jan 14;10:8
pubmed: 21235757
Nat Commun. 2018 May 2;9(1):1769
pubmed: 29720620
Malar J. 2015 Feb 05;14:49
pubmed: 25848972
N Engl J Med. 2009 Jul 30;361(5):455-67
pubmed: 19641202
Antimicrob Agents Chemother. 2017 Nov 22;61(12):
pubmed: 28923866
Int J Parasitol Drugs Drug Resist. 2012 Jul 17;2:191-9
pubmed: 24533280
Am J Trop Med Hyg. 2006 Jul;75(1):146-51
pubmed: 16837722
Malar J. 2013 Nov 25;12:431
pubmed: 24274185
Med Sante Trop. 2016 Jan-Mar;26(1):45-50
pubmed: 26644184
BMC Infect Dis. 2013 Dec 20;13:598
pubmed: 24354627
Emerg Infect Dis. 2018 Aug;24(8):
pubmed: 29798744
BMC Med. 2015 Dec 22;13:305
pubmed: 26695060
N Engl J Med. 2014 Jul 31;371(5):411-23
pubmed: 25075834
Antimicrob Agents Chemother. 2018 Jan 25;62(2):
pubmed: 29229635
Antimicrob Agents Chemother. 2010 Sep;54(9):3537-44
pubmed: 20547801
Lancet Infect Dis. 2015 Jun;15(6):683-91
pubmed: 25877962
Antimicrob Agents Chemother. 2013 Dec;57(12):6196-204
pubmed: 24080667
Int J Antimicrob Agents. 2017 Jun;49(6):754-756
pubmed: 28450175
Emerg Infect Dis. 2016 May;22(5):841-5
pubmed: 27088703
Malar J. 2007 Apr 16;6:44
pubmed: 17437625